462 related articles for article (PubMed ID: 17009262)
1. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
[TBL] [Abstract][Full Text] [Related]
2. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
3. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus.
Jimenez-Caliani AJ; Jimenez-Jorge S; Molinero P; Rubio A; Guerrero JM; Osuna C
J Pineal Res; 2008 Sep; 45(2):204-11. PubMed ID: 18507713
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
Sadanaga A; Nakashima H; Masutani K; Miyake K; Shimizu S; Igawa T; Sugiyama N; Niiro H; Hirakata H; Harada M
Arthritis Rheum; 2005 Dec; 52(12):3987-96. PubMed ID: 16320345
[TBL] [Abstract][Full Text] [Related]
5. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
7. Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus.
Zeller GC; Hirahashi J; Schwarting A; Sharpe AH; Kelley VR
J Am Soc Nephrol; 2006 Jan; 17(1):122-30. PubMed ID: 16291836
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive effects of (2R,5R)-6-heptyne-2,5-diamine, an inhibitor of polyamine synthesis: II. Beneficial effects on the development of a lupus-like disease in MRL-lpr/lpr mice.
Claverie N; Pasquali JL; Mamont PS; Danzin C; Weil-Bousson M; Siat M
Clin Exp Immunol; 1988 May; 72(2):293-8. PubMed ID: 3409547
[TBL] [Abstract][Full Text] [Related]
9. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
Zhai ZF; Zhou CL; Zhong BY; Ao JH; Hao F
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):406-10. PubMed ID: 18581896
[TBL] [Abstract][Full Text] [Related]
10. The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.
Apelgren LD; Bailey DL; Fouts RL; Short L; Bryan N; Evans GF; Sandusky GE; Zuckerman SH; Glasebrook A; Bumol TF
Cell Immunol; 1996 Oct; 173(1):55-63. PubMed ID: 8871601
[TBL] [Abstract][Full Text] [Related]
11. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
12. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice.
Nicoletti F; Di Marco R; Zaccone P; Xiang M; Magro G; Grasso S; Morrone S; Santoni A; Shoenfeld Y; Garotta G; Meroni P
Eur J Immunol; 2000 Feb; 30(2):438-47. PubMed ID: 10671199
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
Schwarting A; Paul K; Tschirner S; Menke J; Hansen T; Brenner W; Kelley VR; Relle M; Galle PR
J Am Soc Nephrol; 2005 Nov; 16(11):3264-72. PubMed ID: 16221871
[TBL] [Abstract][Full Text] [Related]
14. Lupus nephritis reoccurs following transplantation in the lupus prone mouse.
Hamar P; Wang M; Godo M; Kokeny G; Rosivall L; Ouyang N; Heemann U
Lupus; 2010 Feb; 19(2):175-81. PubMed ID: 19946036
[TBL] [Abstract][Full Text] [Related]
15. Effect of combining ACE inhibitor and statin in lupus-prone mice.
Shimazu H; Kinoshita K; Hino S; Yano T; Kishimoto K; Nagare Y; Nozaki Y; Sugiyama M; Ikoma S; Funauchi M
Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731
[TBL] [Abstract][Full Text] [Related]
16. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
17. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
18. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
Faust J; Menke J; Kriegsmann J; Kelley VR; Mayet WJ; Galle PR; Schwarting A
Arthritis Rheum; 2002 Nov; 46(11):3083-95. PubMed ID: 12428253
[TBL] [Abstract][Full Text] [Related]
19. Knocking out of CD38 accelerates development of a lupus-like disease in lpr mice.
Viegas MS; Silva T; Monteiro MM; do Carmo A; Martins TC
Rheumatology (Oxford); 2011 Sep; 50(9):1569-77. PubMed ID: 21586522
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration.
Licht R; van Bruggen MC; Oppers-Walgreen B; Rijke TP; Berden JH
Arthritis Rheum; 2001 Jun; 44(6):1320-30. PubMed ID: 11407691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
